KINE Biotech, a biotech company based in Taipei, Taiwan, is presently in the advanced preclinical phase. The company specializes in the AI-driven
development of innovative immunotherapies, focusing specifically on antibody-cytokine fusion proteins (ACFPs) that target critical tumor markers or immune checkpoints. KN07 and KN26, the primary programs of KINE Biotech, are tumor-activated αPDL1-IL2v and αPD1-IL2v ACFPs, respectively. These ACFP have exhibited a significant improvement in anticancer efficacy across various murine tumor models in comparison with conventional immune checkpoint inhibitors (ICI).
KINE Biotech welcomes strategic partnerships and out-licensing opportunities to advance the application of our proprietary cytokine-engineering platform. Our technology enables the generation of tailored interleukin variants that can be fused with antibodies to create next-generation biologics with enhanced immune modulation. In oncology, our IL2Rβγc-biased IL2 and IL15-based variants drive strong antitumor immunity when paired with checkpoint inhibitors or tumor-targeting antibodies. Separately, for autoimmune and inflammatory diseases, we offer IL2Rα-biased IL2 variants that selectively expand regulatory T cells (Tregs), providing an approach to restore immune tolerance. We welcome collaboration with biopharma partners interested in developing innovative immunotherapies in either domain—oncology or immune regulation—based on clearly defined mechanisms of action and therapeutic goals.
© Copyright 2025. All Rights Reserved